Remembrance of things past — discontinuation of second-generation tki therapy for cml

Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR–ABL1 tyrosine-kinase inhibitor (TKI) therapy

after a sustained deep molecular response remain in remission for longer than 1 year. Importantly, the interim findings suggest that prior response to first-line TKI treatment might predict

relapse risk after treatment discontinuation. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access

through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to

this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy

now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support REFERENCES * Baccarani, M. _ et al_. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. _Blood_ 122, 872–884 (2013). Article  CAS  Google

Scholar  * Mahon, F. X. _ et al_. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the

prospective, multicentre Stop Imatinib (STIM) trial. _Lancet Oncol._ 11, 1029–1035 (2010). Article  CAS  Google Scholar  * Rousselot, P. _ et al_. Loss of major molecular response as a

trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. _J. Clin.

Oncol._ 32, 424–430 (2014). Article  CAS  Google Scholar  * Rea, D. _ et al_. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI

study. _Blood_ http://dx.doi.org/10.1182/blood-2016-09-742205 (2016). * Ross, D. M. _ et al_. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal

residual disease: results from the TWISTER study. _Blood_ 122, 515–522 (2013). Article  CAS  Google Scholar  * Hochhaus, A. _ et al_. Treatment-free remission (TFR) in patients (pts) with

chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: results from the ENESTFreedom study [abstract]. _J. Clin. Oncol._ 34, 7001 (2016). Article  Google

Scholar  * Hughes, T. P. _ et al_. Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup

analysis from ENESTop [abstract]. _Blood_ 128, 792 (2016). Article  Google Scholar  * Shah, N. P. _ et al_. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid

leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib — the DASfree Study [abstract]. _Blood_ 128, 1895 (2016). Google Scholar  * Imagawa, J. _ et al_. Discontinuation

of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. _Lancet Haematol._ 2,

e528–e535 (2015). Article  Google Scholar  * Ross, D. M. _ et al_. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease

features. _Haematologica_ 96, 1720–1722 (2011). Article  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Timothy P. Hughes and David M. Ross are at the

Cancer Theme, South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, South Australia 5001, Australia., Timothy P. Hughes & David M. Ross Authors * Timothy P.

Hughes View author publications You can also search for this author inPubMed Google Scholar * David M. Ross View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to Timothy P. Hughes. ETHICS DECLARATIONS COMPETING INTERESTS T.P.H. and D.M.R. declare that they have received research funding and honoraria

from Ariad, Bristol-Myers Squibb, and Novartis. POWERPOINT SLIDES POWERPOINT SLIDE FOR TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hughes,

T., Ross, D. Remembrance of things past — discontinuation of second-generation TKI therapy for CML. _Nat Rev Clin Oncol_ 14, 201–202 (2017). https://doi.org/10.1038/nrclinonc.2017.11

Download citation * Published: 07 February 2017 * Issue Date: April 2017 * DOI: https://doi.org/10.1038/nrclinonc.2017.11 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative